| Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers (NCT04611139) | HonorHealth Research Institute | 2021-12-31 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer (NCT05226507) | Nuvectis Pharma, Inc. | 2021-12-31 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (NCT04575935) | M.D. Anderson Cancer Center | 2020-08-05 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors (NCT03641287) | University of Washington | 2018-12-05 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03587311) | National Cancer Institute (NCI) | 2018-10-12 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02923739) | M.D. Anderson Cancer Center | 2017-05-05 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02713386) | NRG Oncology | 2016-11-14 |
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02853318) | Roswell Park Cancer Institute | 2016-09-01 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02122185) | University of Chicago | 2015-02-25 |
| Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT02283658) | Mayo Clinic | 2014-11-14 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT02101775) | National Cancer Institute (NCI) | 2014-07-21 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (NCT02142803) | National Cancer Institute (NCI) | 2014-05-20 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT02068794) | Mayo Clinic | 2014-04-25 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT02111941) | Mayo Clinic | 2014-04-14 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |
| EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01489371) | Gynecologic Oncology Group | 2012-07-09 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00719303) | Gynecologic Oncology Group | 2012-06-18 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01504126) | M.D. Anderson Cancer Center | 2012-03-09 |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT01459380) | National Cancer Institute (NCI) | 2011-10-11 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (NCT01275664) | Gynecologic Oncology Group | 2011-06-01 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (NCT01294293) | Gynecologic Oncology Group | 2011-03-01 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00888615) | GOG Foundation | 2010-12-13 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT01167712) | National Cancer Institute (NCI) | 2010-09-27 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (NCT01116648) | National Cancer Institute (NCI) | 2010-04-14 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT01097746) | M.D. Anderson Cancer Center | 2010-04-14 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01074411) | National Cancer Institute (NCI) | 2010-04-05 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (NCT01080521) | Gynecologic Oncology Group | 2010-04-01 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616) | National Cancer Institute (NCI) | 2009-12-01 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00989651) | National Cancer Institute (NCI) | 2009-10-28 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00951496) | National Cancer Institute (NCI) | 2009-08-11 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00565851) | National Cancer Institute (NCI) | 2007-12-06 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy (NCT00466960) | University of Washington | 2006-05-01 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00262847) | National Cancer Institute (NCI) | 2005-09-01 |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer (NCT00357448) | University of Washington | 2005-04-01 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer (NCT00108745) | GOG Foundation | 2005-03-21 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00079430) | National Cancer Institute (NCI) | 2004-06-01 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) (NCT00085358) | National Cancer Institute (NCI) | 2004-05-01 |
| Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma (NCT00059787) | National Cancer Institute (NCI) | 2003-04-01 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer (NCT00060359) | Gynecologic Oncology Group | 2003-04-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer (NCT00004221) | Gynecologic Oncology Group | 1999-11-01 |
| Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer (NCT00002913) | National Cancer Institute (NCI) | 1996-12-01 |